Pushing PCR Further

A historic innovation

Since 1983, Roche has pioneered the advancement of PCR analysis, which is recognized as a gold standard in laboratory diagnostics. The cobas® Liat® PCR System replicates extracted DNA or RNA from patient samples to accurately identify infectious diseases. Using Roche PCR technology, laboratory-quality sensitivity and specificity are achieved across assays, significantly reducing the risk of false negative and false positive results.1

cobas-liat-historic-innovation-image

cobas® SARS-CoV-2 & Influenza A/B1

SARS-CoV-2 & Influenza A/B

Sensitivity: 97.7%

Specificity: 93.3%

cobas® Strep A2

Strep A

Sensitivity: 97.7%

Specificity: 93.3%

cobas® Influenza A/B3

Influenza A

Sensitivity: 97.5%

Specificity: 97.9%

Influenza B

Sensitivity: 96.9%

Specificity: 97.9%

cobas® Influenza A/B & RSV4

Influenza A

Sensitivity: 97.5%

Specificity: 97.9%

Influenza B

Sensitivity: 96.9%

Specificity: 97.9%

cobas® Cdiff5

Cdiff

Sensitivity*: 93.5%

Specificity*: 96.4%

Quality without compromise

Patients deserve the best care possible—that means reliable results in a reasonably short amount of time. Current diagnostic options offer a trade-off between speed or accuracy, and since many diseases present similar symptoms at early stages, the need for a reliably accurate point-of-care testing solution is high.

Explore the pros and cons of current diagnostic options

Signs & symptoms

sign-symptopms-mobile-thumb-image

Pro

Quick diagnosis, based on knowledge and experience

Con

Could lead to incorrect antibiotic treatment

On-site rapid antigen test

on-site-rapid-tests-mobile-thumb-image

Pro

Fast results, easy to use

Con

Potentially less accurate, with uncertainty around negative results

Lab cultures

lab-cultures-mobile-thumb-image

Pro

Highly accurate and definitive

Con

Prolongs time for patient diagnosis

Based on Nobel Prize-winning PCR technology, you can be confident that the cobas® Liat® PCR System supports you in delivering the best patient care possible.
Explore the cobas® Liat® System


*Compared to the cobas® SARS-CoV-2 Test on cobas® 6800/8800 Systems; EUA data.
Compared to culture and latex agglutination for Strep A typing; CLIA data.
Compared to viral culture; CLIA data.
§Compared to an FDA-cleared laboratory based multiplexed real-time reverse transcriptase PCR (RT-PCR) test; combined PPA and NPA from retrospective and prospective samples for influenza A and influenza B, respectively.
#Compared to direct culture.

cobas® SARS-CoV-2 & Influenza A/B has Emergency Use Authorisation (EUA) and is CE-IVD cleared [package insert, V01]. cobas® Strep A, cobas® Influenza A/B and cobas® Influenza A/B & RSV are CE-IVD and FDA 510(k) cleared; CLIA waived. cobas® Cdiff is CE-IVD cleared.

References: 1. cobas® SARS-CoV-2 & Influenza A/B [package insert V01], Pleasanton, CA: Roche Molecular Systems, Inc., 2020. 2. cobas® Strep A. Pleasanton, CA: Roche Molecular Systems, Inc., 2016 [package insert]. 3. cobas® Influenza A/B [package insert]. Pleasanton, CA: Roche Molecular Systems, Inc., 2015. 4. cobas® Influenza A/B & RSV [package insert]. Pleasanton, CA: Roche Molecular Systems, Inc., 2016. 5. cobas® Cdiff [package insert].